During a recent virtual fireside chat, I met with industry experts Courtney Hudson, President and Founder of Carebox; and Cyntha Griffo; Director of Communications and Education at the Abramson Cancer Center at the University of Pennsylvania, to discuss the current state of cancer trial matching. This conversation offered the opportunity to learn more about how institutions can benefit from automated cancer trial matching.
Jodi Treharne, Director of Cancer Informatics at Inspirata, also shared her thoughts on how to build the business case for automation from financial, operational and reputational perspectives. This article summarises some of the key takeaways from this insightful conversation.
Current challenges facing trial matching
The session opened to highlight that there’s no shortage of demand to match patients to relevant trials as early as possible. The panel discussed how hospitals are under pressure to enroll more patients into trials in order to speed up the discovery and approval of new medicines. They commented this was especially relevant in the oncology space, where medical breakthroughs can significantly improve outcomes for cancer patients.
The challenge that was highlighted focused on patient matching, which remains a largely manual and cumbersome process. The panel explained that negative downstream impacts on both patients and academic cancer centers.
As one panelist highlighted, “Today, 80% of clinical trials fail to meet recruitment timelines and 25% of investigative sites fail to enroll enough patients. Fewer than one-third of clinicians discuss trial options during treatment planning, and less than 4% of US adults with cancer enroll in clinical trials, leaving an overwhelming number of families frustrated with the process.”
Cynthia Griffo noted that in the course of her work at a large academic cancer centre, she already works with community networks and satellites to fast-track patients into trials.
“But is it really fast?” she notes. “It would definitely be [more smoothly] handled with greater automation. It takes so much work to get to where we are. We have been talking for 20 years about this automation to the point of care. So, it’s not really fast.”
Building a business case for automated cancer trial matching
The session followed-on to explore a recent Inspirata survey into patient match rates and revealed that the average cancer centre seeks to increase patient enrolment in trials by approximately 75%. However, the panel stated current enrolment rates averaging approximately half of this percentage, make a successful business case imperative.
Highlighting the distinct financial and operational advantages of automation to hospital administration is a must. The panel said, “You’d want to look at things like what’s your current enrolment rate today versus what you’re going to be expecting out of the automation…what’s the accrual that you want to see from it?”. Having a good internal understanding of revenue per patient from clinical trials was highlighted: “This enables you to apply multiply that accrual in enrolment by revenue per patient in order to project what the technology is going to cost you over a period of time.”
Operational benefits such as time savings are also important to quantify; Courtney Hudson notes that reducing the workload associated with identifying patients is the most immediate and obvious benefit of automation. “That’s huge, it’s just got to be less work—you can’t do this stuff off the top of your head. Assessing all the patient variables and all the trial variables for every arm of the study is just undoable.”
The panel then explained that when a solution improves clinical research and patient care, it creates intangible benefits to the reputation of the institution and the community it serves. “For the Abramson Cancer Center, an improvement in automation would really allow us to further enhance our benefit to the community,” says Cynthia. “Our message has always been that the dramatic progress made in treating cancer has come from clinical trials. Consequently, patients who participate in trials gain access to the very latest changes in cancer care. To be able to turn this around more rapidly would provide a definite edge in a very competitive area where we are in Pennsylvania.”
Building a case for automating the clinical trial matching process requires a tailored, cross-functional approach due to the diversity of stakeholders. “I would really encourage anybody who’s looking at [automation], to work with your vendor, work with your internal team, determine what’s important to you, and what is the business case for your individual situation,” says Jodi.
Reducing the need to refer patients out; expanding patient options
The session then focused again on Inspirata’s benchmark study and surfaced the frequency in which hospitals or trusts were required to refer patients to clinical trials outside of their institution. 69% of oncologists interviewed were required to refer patients out either occasionally or often, the results stated.
From Courtney’s perspective, she raised that access to accurate, instantaneous, sensible results greatly reduces friction in the matching process. First and foremost, physicians cannot only view matches within their institutions or networks but can also view and offer regional or national trial matches. She provides an example: “While [the University of Pennsylvania] may get the inquiry, in fact, the patient lives closer to another NCI-designated cancer center that has the same trial open. So, you can both figure out the logistics and the geography of where to make the referral to, as well as find anything you’ve got in-house. But you’ve got to have…those results be accurate; you need those results instantaneously.”
The session then touched on the benefit in viewing the set of trials that are a match for the patient today, and the ability to look ahead and provide informed patient treatment options based on precise, timely information that considers eligibility windows is appealing.
Courtney continues: “So you can see what’s open today that’s a match for the patient. Or…do a deeper dive into the trials we have open today…or that are open nationally, that have a particular biomarker requirement. And while the patient might be too early for that study…you can see that it’s there as the next option you might tee up for the patient.”
The session then closed with a summary to highlight that automated cancer trial matching not only significantly reduces the manual burden on physicians or nurse coordinators, it also allows greater productivity to cover much larger sets of trials and patients.
To watch the in-depth discussion, please click here.